Level C· Early human research exploring benefitsRetrospective StudyPubMed

Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation.

Kamo N., Kaido T., Hamaguchi Y., Okumura S., Kobayashi A., Shirai H.

Retrospective Study with a reported sample of 46 on Back & Spine, published in Clin Nutr (2018) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Clin Nutr (2018)
Country
England
Reported sample size
46
Source database
PubMed
PMID
30482562
DOI
10.1016/j.clnu.2018.09.019

Abstract (original English)

Sarcopenia is known to be a poor prognostic factor after liver transplantation (LT). However, the significance of obesity in combination with sarcopenia (sarcopenic obesity) remains unclear. This study examined the impact of sarcopenic obesity on outcomes after living donor LT (LDLT). We retrospectively analyzed 277 adult patients who underwent LDLT at our center between January 2008 and June 2016. Body composition parameters including skeletal muscle mass index (SMI), intramuscular adipose tissue content (IMAC), visceral fat area (VFA), and visceral-to-subcutaneous adipose tissue area ratio (VSR) were evaluated by preoperative plain computed tomography imaging at the level of the third lumbar vertebra. This study defined sarcopenic obesity as a low SMI (male <40.31 cm 2 /m 2 ; female <30.88 cm 2 /m 2 ) with VFA ≥100 cm 2 or body mass index (BMI) ≥25 kg/m 2 . We examined outcomes among four groups: nonsarcopenic/nonobesity (NN), nonsarcopenic/obesity (NO), sarcopenic/nonobesity (SN), and sarcopenic/obesity (SO) groups. On the basis of VFA, 1/5-year overall survival (OS) rates in patients of SN (n = 46, 59%/46%, P < 0.001) and SO (n = 9, 56%/56%, P = 0.338) groups were lower than those in patients of the NN group (86%/80%). On the other hand, on the basis of BMI, 1/5-year OS rates in patients of SN (n = 49, 59%/52%, P < 0.001) and SO (n = 6, 50%/17%, P = 0.002) groups were signi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAdolescentAdultAgedBody CompositionBody Mass IndexFemaleHumansLiver TransplantationLiving Donors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research